Treatment of bipolar disorders and metabolic syndrome: Implications for primary care

Postgraduate Medicine

Volumn 121, Issue 5, 2009, Pages 140-144

  Bell, Paul F ^a   McKenna, James P ^a   Roscoe, Brandon M ^b  

^a Heritage Valley Health System   (United States)

^b ALBERT LEA EYE CLINIC   (United States)

Author keywords

Antipsychotic medication; Bipolar disorders; Metabolic syndrome; Mood disorders

Indexed keywords

ANTICONVULSIVE AGENT; ARIPIPRAZOLE; CLOZAPINE; LITHIUM; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

BIPOLAR DEPRESSION; BIPOLAR DISORDER; BIPOLAR MANIA; CARDIOVASCULAR DISEASE; DIET; DRUG EFFICACY; DRUG SAFETY; EXERCISE; HUMAN; INFORMATION RETRIEVAL; METABOLIC SYNDROME X; MOOD DISORDER; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT MONITORING; PRACTICE GUIDELINE; PREVALENCE; PRIMARY MEDICAL CARE; REVIEW; RISK FACTOR;

ADULT; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; CHRONIC DISEASE; COMORBIDITY; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MEDICATION ADHERENCE; METABOLIC SYNDROME X; PREVALENCE; PRIMARY HEALTH CARE; RISK MANAGEMENT;

EID: 78649257307     PISSN: 00325481     EISSN: 19419260     Source Type: Journal    
DOI: 10.3810/pgm.2009.09.2060     Document Type: Review

References (39)

1. Kessler R, Stafford D. Primary care is the de facto mental health system. In: Kessler R, Stafford D, eds. Collaborative Medicine Case Studies. New York, NY; Springer 2008:9-21.
2. Lieberman JA. The use of antipsychotics in primary care. Primary Care Companion Journal of Clinical Psychiatry. 2003;5( suppl 3):3-8.
3. US Preventive Services Task Force. Screening for depression: recommendations and rationale. Am Fam Physician. 2002;66(4):647-650.
4. Manning JS. Bipolar disorder in primary care. J Fam Pract. 2003(suppl): S6-S9.
5. Tohen M, Angst J. Epidemiology of bipolar disorder. In: Tsuang MT, Tohen M, eds. Textbook in Psychiatric Epidemiology. 2nd ed. New York, NY: John Wiley and Sons; 2002:427-444.
6. Hirschfeld RM, Lewis L, Vornik LA. Perceptions and impact of bipolar disorder: how far have we really come? Results of the national depressive and manic-depressive association 2000 survey of individuals with bipolar disorder. J Clin Psychiatry. 2003;64(2):161-174.
7. Citrome L, Goldberg JF. Commentary: bipolar disorder is potentially fatal. Postgrad Med. 2005;117(2):9-11. (Pubitemid 40261961)
8. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Text Revision. Washington DC: American Psychiatric Association; 1994.
9. Judd LL, Akiskal HS, Schettler PJ, et al. The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch Gen Psychiatry. 2002;59(6):530-537.
10. Judd LL, Akiskal HS, Schettler PJ, et al. A prospective investigation of the natural history of the long-term weekly symptomatic status of bipolar II disorder. Arch Gen Psychiatry. 2003;60(3):261-269.
11. Citrome L, Goldberg JF. The many faces of bipolar disorder. How to tell them apart. Postgrad Med. 2005;117(2):15-16.
12. Cusack JR. Bipolar disorder: How to recognize and treat in primary care. Consultant. 2002;42:912-926.
13. Marken PA, Pies RW. Emerging treatment for bipolar disorder: safety and adverse effects profiles. Ann Pharmacother. 2006;40(2): 276-285.
14. American Diabetes Association; American Psychiatric Association; American Association of Clinical Endocrinologists; North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care. 2004;27(2):596-601.
15. Newcomer JW. Metabolic considerations in the use of antipsychotic medications: a review of recent evidence. J Clin Psychiatry. 2007;68(suppl 1):20-27.
16. Lambert BL, Cunningham FE, Miller DR, Dalack GW, Hur K. Diabetes risk associated with the use of olanzapine, quetiapine, and risperidone in Veterans Health Administration patients with schizophrenia. Am J Epidemiol. 2006;164(7):672-681. (Pubitemid 44453496)
17. Keck PE, McElroy SL. Bipolar disorder, obesity, and pharmacotherapy- associated weight gain. J Clin Psychiatry. 2003;64(12):1426-1435.
18. Galassi A, Reynolds K, He J. Metabolic syndrome and risk of cardiovascular disease: a meta-analysis. Am J Med. 2006;119(10): 812-819. (Pubitemid 44415613)
19. Critchley J, Capewell S. Smoking cessation for the secondary prevention of coronary heart disease. Cochrane Database Syst Rev. 2004;(1):CDO03041.
20. Krishnan KR. Psychiatric and medical comorbidity of bipolar disorder. Psychosomatic Med. 2005;67:1-8.
21. McIntyre RS, Konarski JZ, Misener VL, Kennedy SH. Bipolar disorder and diabetes mellitus: epidemiology, etiology, and treatment implications. Ann Clin Psychiatry. 2005;17(2):83-93.
22. Kupfer DJ. The increasing medical burden in bipolar disorder. JAMA. 2005;293(2):2528-2530.
23. The American Heart Association and the National Heart, Lung, and Blood Institute. 2008. http://www.americanheart.org/presenter. jhtml?identifier=4756. Accessed December 2008.
24. Narasimhan M, Bailey SB. Schizophrenia, metabolic syndrome, and antipsychotics challenges, controversies, and clinical management. Psychiatric Times. March 2008. http://www.psychiatrictimes.com./schizophrenia/article/10168/ 1147401. Accessed December 2008.
25. Leslie DL, Rosenheck RA. Incidence of newly diagnosed diabetes attributable to atypical antipsychotic medications. Am J Psychiatry. 2004;161(9):1709-1711.
26. Koro CE, Fedder DO, L'Italien GJ, et al. An assessment of the independent effects of olanzapine and risperidone exposure on the risk of hyperlipidemia in schizophrenic patients. Arch Gen Psychiatry. 2002;59(11):1021-1026.
27. Brixner DI, Said Q, Corey-Lisle PK, et al. Naturalistic impact of second generation antipsychotics on weight gain. Ann Pharmacother. 2006;40(4):626-632.
28. Mallya A, Chawla P, Boyer SK, DeRosear L. Resolution of hyperglycemia on risperidone discontinuation: a case report. J Clin Psychiatry. 2002;63(5):453-454. (Pubitemid 34507227)
29. Croarkin PE, Jacobs KM, Bain BK. Diabetic ketoacidosis associated with resperidone treatment? Psychosomatics. 2000;41(4):369-370.
30. Lindenmayer JP, Nathan AM, Smith RC. Hyperglycemia associated with the use of atypical antipsychotics. J Clin Psychiatry. 2001;62(suppl 23):30-38.
31. Haupt DW, Newcomer JW. Risperidone-associated diabetic ketoacidosis. Psychosomatics. 2001;42(3):279-280.
32. Wirshing DA, Pierre JM, Eyeler J, Weinbach J, Wirshing WC. Risperidone-associated new-onset diabetes. Biol Psychiatry. 2001;50(2): 148-149.
33. Newcomer JW, Nasrallah HA, Loebel AD. The atypical antipsychotic therapy and metabolic issues national survey: practice patterns and knowledge of psychiatrists. J Clin Psychopharmacol. 2004;24(5 suppl 1): S1-S6.
34. Barnett AH, Mackin P, Chaudhry I, et al. Minimising metabolic and cardiovascular risk in schizophrenia: diabetes, obesity, and dyslipidaemia. J Psychopharmacol. 2007;21(4):357-373.
35. Lipkovich I, Citrome L, Perlis R, et al. Early predictors of substantial weight gain in bipolar patients treated with olanzapine. J Clin Psychopharmacol. 2006;26(3): 316-320. (Pubitemid 43804625)
36. Prochaska JO, DiClemente CC. Transtheoretical therapy: toward a more integrative model of change. Psychotherapy, Theory, Research, and Practice. 1982;19:161-173.
37. Vallis M, Ruggiero L, Greene G, et al. Tages of change for healthy eating in diabetes: relation to demographic, eating-related, health care utilization, and psychosocial factors. Diabetes Care. 2003;26(5):1468-1474.
38. Rollnick S, Miller WR. What is motivational interviewing? Behav Cogn Psychother. 1995;23:325-334.
39. Welch G, Rose G, Ernst MA. Motivational interviewing and diabetes: what is it, how is it used, and does it work? Diabetes Spectrum. 2006;19:5-11.